|
Sunday, 08/01/2010
|
Partnership in New Drug Developments
Ji Zhang, Sanofi-Aventis; Hui Quan, sanofi-aventis; Alex Boddy, sanofi-aventis; Peng-Liang Zhao, sanofi-aventis; Stan Young, National Institute for Statistical Science
2:25 PM
|
|
Monday, 08/02/2010
|
Doing Better Than Average: Tailored Therapeutics in Drug Development
Stan Young, National Institute for Statistical Science; Stephen J. Ruberg, Eli Lilly and Company; Frank Rockhold, GlaxoSmithKline; Sue-Jane Wang, FDA; Stephen Senn, University of Glasgow
1:00 AM
|
Global Drug Development in a Rapidly Changing World, with Examples from HCV/HIV Trials
Regis Vilchez, Merck Research Laboratories; Carmen Mak, Merck Research Laboratories
9:35 AM
|
An Algorithm to Evaluate Probability of Success for Decisionmaking in Early Drug Development
Annie Wang, Abbott Laboratories; Narinder Nangia, Abbott Laboratories
9:50 AM
|
Statistics in Biopharmaceutical Research: Application of Biomarkers in Drug Development
Aloka Chakravarty, FDA; Mark Rothmann, FDA; Rajeshwari Sridhara , FDA
2:05 PM
|
Applications of 'Learn' Phase Adaptive Designs
Jose Carlos Pinheiro, Johnson & Johnson; Chyi-Hung Hsu, Novartis Pharmaceuticals Corporation
2:05 PM
|
Overcoming the Winner's Curse to Identify Biomarkers with Clinical Relevance in Drug Development
Lei Shen, Eli Lilly and Company; Haoda Fu, Eli Lilly and Company
3:20 PM
|
|